Table 3.
Basal expression of surface markers in PBMCs of patients with RA according to CD154 genotype
| Surface markers | 24CAs (n = 13) | Non-24CAs (n = 15) | P |
| CD16/CD56a | 16.07 ± 10.78 | 12.38 ± 10.24 | n.s. |
| CD19a | 6.42 ± 3.12 | 4.17 ± 3.01 | 0.018 |
| CD3/CD8a | 17.24 ± 7.66 | 22.37 ± 6.67 | n.s. |
| CD3/CD4a | 44.40 ± 14.79 | 41.22 ± 13.11 | n.s. |
| CD4/CD69b | 14.09 ± 19.02 | 7.48 ± 10.25 | n.s. |
| CD4/CD25b | 59.59 ± 18.04 | 41.19 ± 22.84 | 0.036 |
| CD4/CD154b | 4.28 ± 3.81 | 8.12 ± 5.73 | 0.033 |
Results are means ± SD for cells expressing the indicated surface markers, quantified by flow cytometry. Differences were evaluated by the Mann–Whitney U test. n, number of samples analyzed; n.s., non significant; PBMCs, peripheral blood mononuclear cells. aReferred to total lymphocytes; breferred to total CD4+ lymphocytes.